Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
EP3532072B1	TREATMENT OF GLAUCOMA	The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and normalization of intraocular pressure, a neuroprotective effect in terms of preserving retinal ganglion cells and retinal nerve fiber layer and dissolves established trabecular meshwork scar elements.	1. Dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight equal to or below 10 000 Da for use in treating, inhibiting or preventing glaucoma in a subject. 3. Dextran sulfate, or said pharmaceutically acceptable salt thereof, having an average molecular weight equal to or below 10 000 Da for use in reducing intraocular pressure in a subject suffering from glaucoma. 5. Dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight equal to or below 10 000 Da for use in treating, inhibiting or preventing ocular hypertension in a subject. 7. Dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight equal to or below 10 000 Da for use in inhibiting loss of retinal ganglion cells and reduction of retinal nerve fiber layer in a subject suffering from glaucoma, preferably open-angle glaucoma, and/or ocular hypertension. 9. Dextran sulfate, or said pharmaceutically acceptable salt thereof, for use according to any of the claims 1 to 8, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, is formulated for systemic administration to said subject. 12. Dextran sulfate, or said pharmaceutically acceptable salt thereof, for use according to any of the claims 1 to 11, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average sulfur content in a range from 15 to 20 %, preferably 17 %.	TX Medic AB, 263 03 Viken, SE, 101494196 | TX MEDIC AB	2020-01-01	2017-05-17
EP3329929B1	PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DRY EYES	The present invention relates to a pharmaceutical composition for preventing or treating dry eye, the pharmaceutical composition including, as an active component, a novel peptide is disclosed, wherein it is confirmed that the peptide has effects on improving tear production and corneal surface smoothness for dry eyes induced by desiccation stress and suppressing detachment of corneal epithelial cells, reduction in conjunctival goblet cells, and generation of inflammatory factors, thereby applying a composition including the peptide as an active component to the pharmaceutical composition for preventing or treating dry eye.	1. A pharmaceutical composition for use in preventing or treating dry eye, the pharmaceutical composition comprising, as an active component, a peptide having an amino acid sequence of SEQ ID NO: 1 or 2.	EYEBIO KOREA, Busan 47392, KR, 101846813 | EYEBIO KOREA	2020-01-29	2015-07-30
EP3213763B1	OPHTHALMIC COMPOSITION COMPRISING CYCLOSPORINE AND TREHALOSE	The present invention relates to an ophthalmic composition comprising cyclosporine and trehalose as effective components, a method for producing the same, a method for preventing, improving or treating failure caused by ophthalmoxerosis by administering the same, and a use therefor. The ophthalmic composition according to the present invention has a combination of superior effects on	1. An ophthalmic composition comprising cyclosporine and trehalose as active ingredients, wherein a weight ratio of cyclosporine : trehalose is 1: 20 - 200, and the cyclosporine is present at more than 0.01 weight% - less than 1 weight% and the trehalose is present at 0.5 - 7.5 weight% based on the total composition.	Huons Co. Ltd., Gyeonggi-do 13486, KR, 101652485 | HUONS CO LTD	2020-01-08	2014-10-17

Copyright © Pharma Patents International AG – All rights reserved

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
		ophthalmoxerosis, which can be caused by various factors such as dry air, inflammation, preservatives, etc., and is placed in a variety of states or conditions.				
EP3177284B1	OLIGOMERIC FORMS OF 3-HYDROXYBUTYRATE	The present invention relates to medicaments based on oligomeric forms of 3- hydroxybutyrate, particularly 3-hydroxybutyrate methyl ester dimer (1) and trimer (2), especially for use in treating, preventing and/or inhibiting development of a disorder or condition related to oxidative stress. The present invention relates also to the use of these molecules as antioxidants, and to a method for increasing proliferation and viability of plant cells in the aid of molecules 1and 2.	1. A molecule of general formula I wherein n is an integer 1 or 2, and Z is selected from a carboxylic acid, its pharmaceutically acceptable salt or ester, for use in the treatment of an ophthalmic disorder, wherein said molecule is administered via parenteral, local or gastro-resistant oral administration. 10. A pharmaceutical composition for parenteral, local or gastro-resistant oral administration comprising a molecule of general formula I, wherein n is an integer 1 or 2 and wherein Z is selected from a carboxylic acid, its pharmaceutically acceptable salt and ester, and one or more excipients and preferably also a pharmaceutically suitable carrier, for use in the treatment of an ophthalmic disease.	Oulun Yliopisto, 90014 Oulun Yliopisto, FI, 101821164 | OULUN YLIOPISTO	2020-01-15	2014-07-21
EP3139791B1	SYSTEMS, METHODS, AND KITS FOR CLEANSING AN OCULAR REGION	Systems, methods, and kits useful for cleansing the eyelids and maintaining eyelid hygiene are disclosed. In one embodiment, a system for treating or cleansing an ocular region is disclosed. The system consists essentially of: (A) a tubular applicator, wherein the applicator comprises: (i) a first chamber and a second chamber; and (ii) a sealable element situated between the first chamber and the second chamber, wherein at least the second chamber is substantially pre-filled with an ocular composition, and (B) a dispenser, wherein the dispenser is bonded to an external surface of a first end of the applicator.	1. A system for treating or cleansing an ocular region, the system consisting essentially of: (A) a tubular applicator (110) having a first end (110a) and an opposed second end (110b), the first end having an opening, wherein the tubular applicator consists of: (i) a first chamber (120a); (ii) a second chamber (120b), wherein the first chamber is adjacent the first end of the applicator and the second chamber is adjacent the second end of the of the applicator; (iii) a rupturable sealable element (140) disposed within an internal cavity of the tubular applicator, the sealable element defining the first chamber and the second chamber within the internal cavity; and (iv) a self-saturating dispenser (130) for the ocular composition, wherein the dispenser is bonded to an external surface of a first end of the applicator, wherein the dispenser envelopes the opening at the first end of the applicator, wherein the dispenser comprises an absorbent material selected from the group consisting of foam, sponge, fiber, felt, cotton, rayon, synthetic foam, synthetic sponge, textile and synthetic fiber; and (B) an ocular composition, wherein the second chamber is pre-filled with the ocular composition, wherein rupturing of the sealable element creates a passage between the first and second chambers for the ophthalmic composition to flow from the second chamber to the first chamber and through the opening at the first end, wherein the dispenser is configured to receive a desired amount of the ocular composition through the opening.	Ocusoft Inc., Richmond, Texas 77406, US, 101504542 | OCUSOFT INC	2020-01-01	2014-05-09
EP3137068B1	TREATMENT OF FIBROSIS	The present invention relates an aldehyde dehydrogenase inhibitor for use in the treatment or prevention of fibrosis.	1. An aldehyde dehydrogenase inhibitor for use in the treatment or prevention of ocular mucous membrane pemphigoid (OcMMP), wherein the aldehyde	The University of Birmingham, Edgbaston, Birmingham B15	2020-01-01	2014-05-02

Copyright © Pharma Patents International AG – All rights reserved

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			dehydrogenase inhibitor is tetraethylthioperoxydicarbonic diamide (disulfiram) or 4-(diethylamino)benzaldehyde (DEAB).	2TT, GB, 101194861 | THE UNIV OF BIRMINGHAM		
EP3065761B1	METHOD OF TREATING CONDITIONS OF THE EYE WITH AN ANTI-VEGF DARPIN	Disclosed herein are methods for the treatment of a patient having an exudative age-related macular degeneration and other conditions of the retina by administering a binding protein comprising an ankyrin repeat domain, wherein the binding protein is first administered in 2 to 5 doses, with an interval of 25 to 35 days between each dose, and then is administered in additional doses with a longer interval between doses.	1. A recombinant binding protein comprising an ankyrin repeat domain, for use in a method for treatment of macular degeneration, or for the treatment of a disease of the retina, by inhibiting binding between VEGF-Axxx and VEGFR-2 for improvement of visual acuity in a patient having said disease of the retina, wherein the dose is 0.25 mg to 4 mg, and wherein the recombinant binding protein is to be administered in 2 to 5 doses, with an interval of 25 to 35 days between each dose, wherein the binding protein is to be administered with at least one additional dose, following the 2-5 doses, with an interval of 50 - 115 days between each additional dose, wherein the ankyrin repeat domain is selected from the group consisting of the ankyrin repeat domains of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, in particular SEQ ID NO:3, and wherein the patient is refractory to ranibizumab and/or bevacizumab.	ALLERGAN INC., Irvine, CA 92612, US, 100074706 | ALLERGAN INC	2020-01-08	2013-11-05
EP2814500B1	ERYTHROCYTE-BINDING THERAPEUTICS	Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immimotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.	1. A pharmaceutically acceptable composition comprising: an antigen; an erythrocyte-binding moiety, wherein the erythrocyte-binding moiety is a peptide ligand selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17; wherein the erythrocyte binding moiety is covalently bound to the antigen.	Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, CH, 101322784 | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL	2020-01-08	2012-02-15
EP2701708B1	SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY	Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.	1. A pharmaceutical composition for use in a method of treatment of cancer, comprising the compound NSC350625, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.	The Penn State Research Foundation, University Park, PA 16802, US, 101007366 | PENN STATE RES FOUND	2020-01-22	2011-04-29
EP3348264B1	ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR LOWERING INTRAOCULAR PRESSURE	The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, of enantiomers thereof, of tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.	1. A compound for use in a method of lowering intraocular pressure in a human patient in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising said compound, wherein the compound is 2, 2-dimethyl-propionic acid-3-[(S)-1-(1 H-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester having the following structure: or its hydrates, its solvates, its crystal	ALLERGAN INC., Irvine, CA 92612, US, 100074706 | ALLERGAN INC	2020-01-01	2010-09-16

Copyright © Pharma Patents International AG – All rights reserved

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			forms, its tautomers or a pharmaceutically acceptable salt thereof. 13. A pharmaceutical composition for use in a method of lowering intraocular pressure in a human patient, wherein the composition comprises a compound which is 2, 2-dimethyl-propionic acid-3-[(S)-1-(1H-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester having the following structure: or its hydrates, its solvates, its crystal forms, its tautomers or a pharmaceutically acceptable salt thereof. 14. An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein the pharmaceutical agent is therapeutically effective for lowering intraocular pressure and wherein the packaging material comprises a label which indicates the pharmaceutical agent can be used for lowering intraocular pressure and wherein said pharmaceutical agent comprises an effective amount of a compound which is 2, 2-dimethyl-propionic acid-3-[(S)-1-(1 H-imidazol-4-yl)-ethyl]-2-methyl-benzyl ester having the following structure: or its hydrates, its solvates, its crystal forms, its tautomers or a pharmaceutically acceptable salt thereof.			
EP2944646B1	Oligonucleotide analogues incorporating 5-aza-cytosine therein	Oligonucleotide analogues are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2'-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogues rich in decitabine-de-oxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogues can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogues and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogues, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders.	1. An isolated or synthetic oligonucleotide analogue, or a salt or ester thereof, of general formula 5'-DpG-3' or 5'GpD-3', wherein D is decitabine; p is a phospholinker; and G is deoxyguanosine, for use in treating one of more of the following: a benign tumor selected from hemangiomas, hepatocellular adenoma, cavernous haemangioma, focal nodular hyperplasia, acoustic neuromas, neurofibroma, bile duct adenoma, bile duct cystanoma, fibroma, lipomas, leiomyomas, mesotheliomas, teratomas, myxomas, nodular regenerative hyperplasia, trachomas and pyogenic granulomas; abnormal cell proliferation due to insults to body tissue during surgery, preferably joint surgery, bowel surgery, or cheloid scarring; a disease that produces fibrotic tissue, preferably emphysema; a repetitive motion disorder, preferably carpal tunnel syndrome; a proliferative response associated with organ transplantation; and abnormal angiogenesis, or a disease associated with undesired or abnormal angiogenesis. 13. Use of an isolated or synthetic oligonucleotide analogue, or a salt or ester thereof, of general formula 5'-DpG-3' or 5'GpD-3', wherein D is decitabine; p is a phospholinker; and G is deoxyguanosine, in the manufacture of a medicament for treating one of more of the following: a benign tumor selected from hemangiomas, hepatocellular adenoma, cavernous haemangioma, focal nodular hyperplasia, acoustic neuromas,	Astex Pharmaceuticals Inc., Pleasanton, CA 94588, US, 101526947 | ASTEX PHARMACEUTICALS INC	2020-01-08	2005-09-29

Copyright © Pharma Patents International AG – All rights reserved

Document	Title	Abstract	Independent Claims	Patentee	Granted	Priority
			neurofibroma, bile duct adenoma, bile duct cystanoma, fibroma, lipomas, leiomyomas, mesotheliomas, teratomas, myxomas, nodular regenerative hyperplasia, trachomas and pyogenic granulomas; abnormal cell proliferation due to insults to body tissue during surgery, preferably joint surgery, bowel surgery, or cheloid scarring; a disease that produces fibrotic tissue, preferably emphysema; a repetitive motion disorder, preferably carpal tunnel syndrome; a proliferative response associated with organ transplantation; and abnormal angiogenesis, or a disease associated with undesired or abnormal angiogenesis. 15. An isolated or synthetic oligonucleotide analogue, or a salt or ester thereof, of general formula 5'-DpG-3' or 5'GpD-3', wherein D is decitabine; p is a phospholinker; and G is deoxyguanosine, for use in treating a disease associated with aberrant DNA methylation, wherein said analogue is for administration in a dosing regimen which comprises a treatment cycle, said treatment cycle comprising: intravenous infusion for 1 to 24 hours for 3 to 5 days per treatment cycle at a dose of 0.1 to 1000 mg/m 2 per day. 17. A formulation comprising: (i) an isolated or synthetic oligonucleotide analogue, or a salt or ester thereof, of general formula 5'-DpG-3' or 5'GpD-3', wherein D is decitabine; p is a phospholinker; and G is deoxyguanosine; and (ii) a cancer vaccine.			

Copyright © Pharma Patents International AG – All rights reserved